1. Hauptnavigation
  2. Navigation des Hauptbereiches
  3. Inhalt der Seite

Klinische Studien zum malignen Melanom

Kontaktdaten für Klinische Studien

Für Studienanfragen steht Ihnen unser Dermato-Onkologisches Team zur Verfügung.

Tel.-Nr.: 0621-383-4450 oder 0621-383-3905

e-mail: dermato.onkologie@umm.de

Klinische Studien mit möglichem Studieneinschluss

- MSD  MK-3475

Randomized, Phase II study of the PD-1 inhibitor MK-3475 versus chemotherapy in patients with advanced melanoma

- GSK BRF115532 - COMBI-AD

Randomisierte, doppelblinde Phase III-Studie zur Dabrafenib in Kombination mit Trametinib im Vergleich zu zwei Placebos bei der adjuvanten Behandlung des Hochrisiko-Melanoms mit BRAF-V600-Mutation nach chirurgischer Resektion

- Roche GO28141  co-BRIM

A Phase III, double-blind, placebo-controlled study of vemurafenib + placebo versus vemurafenib in combination with GDC-0973 (MEK-inhibitor) in previously untreated BRAFV600-mutation positive patients with unresectable locally advanced or metastatic melanoma  

- Roche GO27826

A Phase III, randomized, double blind, placebo-controlled study of vemurafenib  (RO5185426) adjuvant therapy in patients with surgically resected, cutaneous BRAF-mutant melanoma at high risk for recurrence

- BMS IMAGE

A multi-national, prospective, observational study in patients with unresectable or metastatic melanoma 

- ROCHE ZESS

A prospective safety study of patients with BRAFV600 mutation-positive unresectable or metastatic melanoma treated with vemurafenib.

-  AB Science AB08026

A prospective, multicenter, randomized, open-label, active-controlled, two-parallel groups, phase 3 study to compare the efficacy and safety of masitinib at 7.5 mg/kg/day to dacarbazine in the treatment of patients with non-resectable or metastatic stage 3 or stage 4 melanoma carrying a mutation in the juxta membrane domain of c-kit

-  ADO - Sentinel Studie

Kontrollierte und prospektiv randomisierte Therapiestudie zum Vergleich einer radikalen Lymphadenektomie versus Beobachtung bei Patienten mit malignem Melanom >1,0 mm Tumordicke und positivem Wächter-Lymphknoten

Klinische Studien aktuell kein Studieneinschluss mehr möglich

GSK MEK116513 - COMBI-v

A Phase III, randomisied, open-label study comparing the combination of the BRAF inhibitor, dabrafenib, and the MEK inhibitor, trametinib, to the BRAF inhibitor venmurafenib in subjects with unresectable (Stage IIIc) or metastatic (Stage IV) BRAF V600E/K mutation positive cutaneous melanoma

GSK PRAME

An open, dose-escalation Phase I/II study to assess the safety, immunogenicity and clinical activity of recPRAME + AS15 Antigen-Specific Cancer Immunotherapeutic as first-line treatment of patients with PRAME-positive metastatic melanoma

ROCHE BRAIN-METS

An open-label, single-arm phase II, multicenter study to evaluate the efficacy of Vemurafenib in patients with brain metastases.

GSK MEK115306 - COMBI-d

Randomisierte, doppelblinde Studie der Phase III zum Vergleich der Kombination des BRAF-Hemmers Dabrafenib und des MEK-Hemmers Trametinib mit Dabrafenib und Placebo als First-Line-Therapie bei Patienten mit nicht reserzierbarem (Stadium IIIC) oder metastasiertem (Stadium IV) kutanen Melanom mit BRAF-V600E/K-Mutation

GSK MEK114267

A phase III randomized, open-label study comparing GSK1121212 to chemotherapy in subjects with advanced or metastatic BRAF V600E/K mutation-positive melanoma

DeCOG-MM-PAL11

The IPI - Multibasket Trial in advanced uveal melanoma: Prospective clinical phase II multibasket study in Melanoma patients with advanced disease

ADO ChemoSensMM

Prospectively randomized phase III study of an individualized sensitivity-directed combination chemotherapy versus DTIC as first-line treatment in stage IV metastatic melanoma

ROCHE MO25515

An open-label, multicenter expanded access study of RO5185426 in patients with metastatic melanoma

BMS CA 184-029

Adjuvant immunotherapy with anti-CTLA-4 monoclonal antibody (ipilimumab) versus placebo after complete resection of high-risk Stage III melanoma: a randomized, double-blind Phase III trial of the EORTC Melanoma Group

GSK Predict

Predictive gene signature fore REsponse to recMAGE-A3 in unresecteD metastatIc CuTaneous melanoma Recombinant MAGE-A3 protein (recMAGE-A3) combined with the AS15 immunological Adjuvant System

GSK Derma

A double-blind, randomized, placebo-controlled phase III study to assiss the efficacy of recMAGE-A3+AS15 ASCI as adjuvant therapy in patients with MAGE-A3 positive resected stage III melanoma

BMS CA 184-025

a multicenter, open-label, phase II study of Ipilimumab (MDX-010) extended-treatment Monotherapy or follow-up for patients previously enrolled in Ipilimumab (MDX-010) protocols

BMS CA 184-024

a multicenter, randomized, double-blind, two-arm, phase III Study in Patients with untreated stage III (unresectable) or IV Melanoma receiving Dacarbazine plus 10 mg/kg of Ipilimumab (MDX-010) vs. Dacarbazine with placebo

Letzte Aktualisierung: 08.05.2013 Seitenanfang